-
1
-
-
30044437827
-
American gastroenterological association medical position statement on the management of hepatitis C
-
Dienstag JL, McHutchison JG. American gastroenterological association medical position statement on the management of hepatitis C. Gastroenterology. 2006;130:225-30.
-
(2006)
Gastroenterology
, vol.130
, pp. 225-230
-
-
Dienstag, J.L.1
McHutchison, J.G.2
-
2
-
-
0036828783
-
Course and outcome of hepatitis C
-
Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002;5(5 Suppl 1):S21-9.
-
(2002)
Hepatology
, vol.5
, Issue.5 SUPPL. 1
-
-
Hoofnagle, J.H.1
-
3
-
-
0028202422
-
Geographical distribution of hepatitis C virus genotypes in blood donors: An international collaborative survey
-
McOmish F, Yap PL, Dow BC, et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol. 1994;32:884-92.
-
(1994)
J Clin Microbiol
, vol.32
, pp. 884-892
-
-
McOmish, F.1
Yap, P.L.2
Dow, B.C.3
-
5
-
-
33947421196
-
Genotypes of hepatitis C virus (HCV) among positive Lebanese patients: Comparison of data with that from other Middle Eastern countries
-
Sharara AI, Ramia S, Ramlawi F, et al. Genotypes of hepatitis C virus (HCV) among positive Lebanese patients: Comparison of data with that from other Middle Eastern countries. Epidemiol Infect. 2007;135(3):427-32.
-
(2007)
Epidemiol Infect
, vol.135
, Issue.3
, pp. 427-432
-
-
Sharara, A.I.1
Ramia, S.2
Ramlawi, F.3
-
6
-
-
33644796135
-
Prevalence of viral markers among first-time Arab blood donors in Kuwait
-
Ameen R, Sanad N, Al-Shemmari S, et al. Prevalence of viral markers among first-time Arab blood donors in Kuwait. Transfusion. 2005;45(12):1973-80.
-
(2005)
Transfusion
, vol.45
, Issue.12
, pp. 1973-1980
-
-
Ameen, R.1
Sanad, N.2
Al-Shemmari, S.3
-
7
-
-
57649120879
-
The unexpected discovery of a focus of hepatitis C virus genotype 5 in a Syrian province
-
Antaki N, Haddad M, Kebbewar K, et al. The unexpected discovery of a focus of hepatitis C virus genotype 5 in a Syrian province. Epidemiol Infect. 2009;137(1):79-84.
-
(2009)
Epidemiol Infect
, vol.137
, Issue.1
, pp. 79-84
-
-
Antaki, N.1
Haddad, M.2
Kebbewar, K.3
-
8
-
-
0031670838
-
Hepatitis C virus infection and genotypes in Southern Israel and the Gaza Strip
-
Shemer-Avni Y, El Astal Z, Kemper O, et al. Hepatitis C virus infection and genotypes in Southern Israel and the Gaza Strip. J Med Virol. 1998;56(3):230-3.
-
(1998)
J Med Virol
, vol.56
, Issue.3
, pp. 230-233
-
-
Shemer-Avni, Y.1
El Astal, Z.2
Kemper, O.3
-
9
-
-
0028132879
-
Hepatitis C virus genotype 4 is highly prevalent in central Africa (Gabon)
-
Xu L-Z, Larzul D, Delaporte E, et al. Hepatitis C virus genotype 4 is highly prevalent in central Africa (Gabon). J Gen Virol. 1994;75:2393-8.
-
(1994)
J Gen Virol
, vol.75
, pp. 2393-2398
-
-
Xu, L.-Z.1
Larzul, D.2
Delaporte, E.3
-
10
-
-
0041852686
-
Phylogenetic analysis of hepatitis C virus isolates indicates a unique pattern of endemic infection in Cameroon
-
Ndjomou J, Pybus OG, Matz B. Phylogenetic analysis of hepatitis C virus isolates indicates a unique pattern of endemic infection in Cameroon. J Gen Virol. 2003;84:2333-41.
-
(2003)
J Gen Virol
, vol.84
, pp. 2333-2341
-
-
Ndjomou, J.1
Pybus, O.G.2
Matz, B.3
-
11
-
-
0031765060
-
Prevalence and genotype of hepatitis C virus infection in pregnant women and blood donors in Ghana
-
Wansbrough-Jones MH, Frimpong E, Cant B, et al. Prevalence and genotype of hepatitis C virus infection in pregnant women and blood donors in Ghana. Trans R Soc Tropical Med Hyg. 1998;92:496-9.
-
(1998)
Trans R Soc Tropical Med Hyg
, vol.92
, pp. 496-499
-
-
Wansbrough-Jones, M.H.1
Frimpong, E.2
Cant, B.3
-
12
-
-
80455148814
-
-
(DHS-) This survey is considered the first epidemiological geographical-based survey done in Egypt for many health problems like HCV, nutrition, maternal health care, etc
-
Egypt Demographic and Health Survey (DHS-2008): http://www.measuredhs. com/pubs. This survey is considered the first epidemiological geographical-based survey done in Egypt for many health problems like HCV, nutrition, maternal health care, etc.
-
(2008)
Egypt Demographic and Health Survey
-
-
-
13
-
-
0033831605
-
Genetic epidemiology of hepatitis C virus throughout Egypt
-
Ray SC, Arthur RR, Carella A, et al. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis. 2000;182:698-707.
-
(2000)
J Infect Dis
, vol.182
, pp. 698-707
-
-
Ray, S.C.1
Arthur, R.R.2
Carella, A.3
-
14
-
-
0343376130
-
Unexpected high prevalence of hepatitis C virus genotype 4 in Southern Spain
-
Sanchez Quijano A, Abad MA, Torronteras R, et al. Unexpected high prevalence of hepatitis C virus genotype 4 in Southern Spain. J Hepatol. 1997;27:25-9.
-
(1997)
J Hepatol
, vol.27
, pp. 25-29
-
-
Sanchez Quijano, A.1
Abad, M.A.2
Torronteras, R.3
-
15
-
-
0036197285
-
Changes in the prevalence of hepatitis C virus (HCV) genotype 4 in Calabria, Southern Italy
-
Matera G, Lamberti A, Quirino A, et al. Changes in the prevalence of hepatitis C virus (HCV) genotype 4 in Calabria, Southern Italy. Diagn Microbiol Infect Dis. 2002;42:169-73.
-
(2002)
Diagn Microbiol Infect Dis
, vol.42
, pp. 169-173
-
-
Matera, G.1
Lamberti, A.2
Quirino, A.3
-
16
-
-
17644444758
-
Route of infection, liver histology and response to interferon in patients with chronic hepatitis caused by genotype 4 HCV infection in a Western country
-
Remy AJ, Verdier E, Perney P, et al. Route of infection, liver histology and response to interferon in patients with chronic hepatitis caused by genotype 4 HCV infection in a Western country. J Hepatol. 1998;29:169.
-
(1998)
J Hepatol
, vol.29
, pp. 169
-
-
Remy, A.J.1
Verdier, E.2
Perney, P.3
-
17
-
-
79956074037
-
Management of hepatitis C virus genotype 4: Recommendations of An International Expert Panel
-
Khattab MA, Ferenci P, Stephanos J, et al. Management of hepatitis C virus genotype 4: recommendations of An International Expert Panel. J Hepatol. 2011;54(6):1250-62.
-
(2011)
J Hepatol
, vol.54
, Issue.6
, pp. 1250-1262
-
-
Khattab, M.A.1
Ferenci, P.2
Stephanos, J.3
-
18
-
-
33747797031
-
Treating viral hepatitis side effects, and complications
-
Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis side effects, and complications. Gut. 2006;55:1350-9.
-
(2006)
Gut
, vol.55
, pp. 1350-1359
-
-
Manns, M.P.1
Wedemeyer, H.2
Cornberg, M.3
-
19
-
-
0035934568
-
Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
-
Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-65.
-
(2001)
Lancet
, vol.358
, pp. 958-965
-
-
Manns, M.P.1
McHutchison, J.G.2
Gordon, S.C.3
-
20
-
-
84872261741
-
-
Accepted poster (AASLD). The study showed a similar efficacy for both once weekly Yshaped interferon regimen VS once/2 weeks, this leads to minimizing the side effects and lowering the treatment costs especially in developing countries
-
Ashour MK, Elraziky M, El Akel W, et al. Safety, Dosage and Efficacy of a Novel Y shaped molecule of Pegylated Interferon alpha 2a for Treatment of Chronic HCV. Accepted poster (AASLD 2011). The study showed a similar efficacy for both once weekly Yshaped interferon regimen VS once/2 weeks, this leads to minimizing the side effects and lowering the treatment costs especially in developing countries.
-
(2011)
Safety, Dosage and Efficacy of A Novel y Shaped Molecule of Pegylated Interferon Alpha 2a for Treatment of Chronic HCV
-
-
Ashour, M.K.1
Elraziky, M.2
El Akel, W.3
-
21
-
-
66649111875
-
Evaluation of a novel pegylated interferon alpha-2a (Reiferon Retard®) in Egyptian patients with chronic hepatitis Cgenotype 4
-
This novel cheap molecule of pegylated Interferon showed comparable results to the ordinary known forms of pegylated Interferon in early fibrosis stages (F1, F2)
-
Esmat G, Abdel Fattah S. Evaluation of a novel pegylated interferon alpha-2a (Reiferon Retard®) in Egyptian patients with chronic hepatitis Cgenotype 4. Digestive and Liver Disease Supplement. 2009;3(1):17-19. This novel cheap molecule of pegylated Interferon showed comparable results to the ordinary known forms of pegylated Interferon in early fibrosis stages (F1, F2).
-
(2009)
Digestive and Liver Disease Supplement
, vol.3
, Issue.1
, pp. 17-19
-
-
Esmat, G.1
Abdel Fattah, S.2
-
22
-
-
77958470624
-
Efficacy and safety of a novel pegylated interferon alpha-2a in Egyptian patients with genotype 4 chronic hepatitis C
-
Taha AA, El-Ray A, El-Ghannam M, et al. Efficacy and safety of a novel pegylated interferon alpha-2a in Egyptian patients with genotype 4 chronic hepatitis C. Can J Gastroenterol. 2010;24 (10):597-602.
-
(2010)
Can J Gastroenterol
, vol.24
, Issue.10
, pp. 597-602
-
-
Taha, A.A.1
El-Ray, A.2
El-Ghannam, M.3
-
23
-
-
78650928878
-
New direct-acting antivirals' combination for the treatment of chronic hepatitis C
-
Asselah T, Marcellin P. New direct-acting antivirals' combination for the treatment of chronic hepatitis C. Liver Int. 2011;31 Suppl 1:68-77.
-
(2011)
Liver Int
, vol.31
, Issue.SUPPL. 1
, pp. 68-77
-
-
Asselah, T.1
Marcellin, P.2
-
25
-
-
65449152185
-
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
-
McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827-38.
-
(2009)
N Engl J Med
, vol.360
, pp. 1827-1838
-
-
McHutchison, J.G.1
Everson, G.T.2
Gordon, S.C.3
-
26
-
-
77950817619
-
Telaprevir for previously treated chronic HCV infection
-
McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362:1292-303.
-
(2010)
N Engl J Med
, vol.362
, pp. 1292-1303
-
-
McHutchison, J.G.1
Manns, M.P.2
Muir, A.J.3
-
27
-
-
67650694266
-
Results of a proof of concept study (C210) of Telaprevir Monotherapy and in combination with peginterferon alfa-2a and Ribavirin in treatment-naive genotype 4 HCV patients
-
Benhamou Y, Moussalli J, Ratziu V, et al. Results of a proof of concept study (C210) of Telaprevir Monotherapy and in combination with peginterferon alfa-2a and Ribavirin in treatment-naive genotype 4 HCV patients. J Hepatol. 2009;50:S6.
-
(2009)
J Hepatol
, vol.50
-
-
Benhamou, Y.1
Moussalli, J.2
Ratziu, V.3
-
28
-
-
57049176125
-
Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227)
-
Seiwert SD, Andrews SW, Jiang Y, et al. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob Agents Chemother. 2008;52:4432-41.
-
(2008)
Antimicrob Agents Chemother
, vol.52
, pp. 4432-4441
-
-
Seiwert, S.D.1
Andrews, S.W.2
Jiang, Y.3
-
29
-
-
84861188748
-
Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study
-
Moreno C, Berg T, Tanwandee T, et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol. 2012;56(6):1247-53.
-
(2012)
J Hepatol
, vol.56
, Issue.6
, pp. 1247-1253
-
-
Moreno, C.1
Berg, T.2
Tanwandee, T.3
-
30
-
-
78751634051
-
High rates of early viral response, promising safety profile and lack of resistance related breakthrough in HCV GT 1/4 patients treated with RG7128 plus PegIFN alfa-2a (40 KD)/RBV: Planned Week 12interim analysis from the PROPEL study
-
abstract 81
-
Jensen DM, Wedemeyer H, Herring RW, et al. High rates of early viral response, promising safety profile and lack of resistance related breakthrough in HCV GT 1/4 patients treated with RG7128 plus PegIFN alfa-2a (40 KD)/RBV: Planned Week 12interim analysis from the PROPEL study. Hepatology 2010;52:(abstract 81).
-
(2010)
Hepatology
, vol.52
-
-
Jensen, D.M.1
Wedemeyer, H.2
Herring, R.W.3
-
31
-
-
66149129922
-
The cyclophilin inhibitor Debio 025 combined with PEG IFN alpha2a significantly reduces viral load in treatment-naive hepatitis C patients
-
Flisiak R, Feinman SV, Jablkowski M, et al. The cyclophilin inhibitor Debio 025 combined with PEG IFN alpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology. 2009;49:1460-8.
-
(2009)
Hepatology
, vol.49
, pp. 1460-1468
-
-
Flisiak, R.1
Feinman, S.V.2
Jablkowski, M.3
-
32
-
-
80053951840
-
HCV NS5A inhibitors modulate multiple aspects of NS5A expression
-
Qiu D, Lemm JA, O'Boyle 2nd DR, et al. HCV NS5A Inhibitors Modulate Multiple Aspects of NS5A Expression. J Gen Virol. 2011;92:2502-11.
-
(2011)
J Gen Virol
, vol.92
, pp. 2502-2511
-
-
Qiu, D.1
Lemm, J.A.2
O'Boyle, I.I.D.R.3
-
34
-
-
70350125916
-
The antihepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation
-
Elazar M, Liu M, McKenna SA, et al. The antihepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation. Gastroenterology. 2009;137:1827-35.
-
(2009)
Gastroenterology
, vol.137
, pp. 1827-1835
-
-
Elazar, M.1
Liu, M.2
McKenna, S.A.3
-
35
-
-
48449084880
-
Clinical trial: Randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4
-
Rossignol JF, Kabil SM, El Gohary Y. Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther. 2008;28:574-80.
-
(2008)
Aliment Pharmacol Ther
, vol.28
, pp. 574-580
-
-
Rossignol, J.F.1
Kabil, S.M.2
El Gohary, Y.3
-
36
-
-
67650558979
-
Nitazoxanide for the treatment of chronic hepatitis C New opportunities but new challenges?
-
Mederacke I, Wedemeyer H. Nitazoxanide for the treatment of chronic hepatitis C New opportunities but new challenges? Ann Hepatol. 2009;8:166-8.
-
(2009)
Ann Hepatol
, vol.8
, pp. 166-168
-
-
Mederacke, I.1
Wedemeyer, H.2
-
37
-
-
84872268551
-
Potent Viral Suppression with All-Oral Combination of Daclatasvir (NS5A Inhibitor) and GS-7977 (NS5B Inhibitor), +/-Ribavirin
-
in Treatment-Naive Patients with Chronic HCV GT1, 2, or 3. (EASL). Barcelona, April 18-22, 2012. Abstract 1422
-
Sulkowski M, Gardiner D, Lawitz E, et al. Potent Viral Suppression with All-Oral Combination of Daclatasvir (NS5A Inhibitor) and GS-7977 (NS5B Inhibitor), +/-Ribavirin, in Treatment-Naive Patients with Chronic HCV GT1, 2, or 3. 47th Annual Meeting of the European Association for the Study of the Liver (EASL 2012). Barcelona, April 18-22, 2012. Abstract 1422.
-
(2012)
47th Annual Meeting of the European Association for the Study of the Liver
-
-
Sulkowski, M.1
Gardiner, D.2
Lawitz, E.3
-
38
-
-
84867402086
-
Dual Oral Therapy with the NS5A Inhibitor Daclatasvir (BMS-790052) and NS3 Protease Inhibitor Asunaprevir (BMS-650032) in HCV Genotype 1binfected Null Responders or Ineligible/Intolerant to Peginterferon
-
(EASL) Barcelona, April 18-22, 2012. Abstract 14
-
Suzuki F, Ikeda K, Toyota J, et al. Dual Oral Therapy with the NS5A Inhibitor Daclatasvir (BMS-790052) and NS3 Protease Inhibitor Asunaprevir (BMS-650032) in HCV Genotype 1binfected Null Responders or Ineligible/Intolerant to Peginterferon. 47th Annual Meeting of the European Association for the Study of the Liver (EASL 2012). Barcelona, April 18-22, 2012. Abstract 14.
-
(2012)
47th Annual Meeting of the European Association for the Study of the Liver
-
-
Suzuki, F.1
Ikeda, K.2
Toyota, J.3
-
39
-
-
21144449073
-
Peginterferon a-2b and ribavirin therapy in chronic hepatitis C genotype 4: Impact of treatment duration and viral kinetics on sustained virological response
-
Kamal SM, El Tawil AA, Nakano T, et al. Peginterferon a-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut. 2005;54:858-66.
-
(2005)
Gut
, vol.54
, pp. 858-866
-
-
Kamal, S.M.1
El Tawil, A.A.2
Nakano, T.3
-
40
-
-
67650132966
-
Predictive value of complete and partial early virological response on sustained virological response rates of genotype-4 chronic hepatitis C patients treated with PEG-interferon plus ribavirin
-
Elefsiniotis IS, Vezali E, Mihas C, et al. Predictive value of complete and partial early virological response on sustained virological response rates of genotype-4 chronic hepatitis C patients treated with PEG-interferon plus ribavirin. Intervirology. 2009;52:247-51.
-
(2009)
Intervirology
, vol.52
, pp. 247-251
-
-
Elefsiniotis, I.S.1
Vezali, E.2
Mihas, C.3
-
41
-
-
84856849283
-
Pegylated interferonalpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT
-
Al-Ali J, Siddique I, Varghese R, et al. Pegylated interferonalpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT. Ann Hepatol. 2012;11(2):186-93.
-
(2012)
Ann Hepatol
, vol.11
, Issue.2
, pp. 186-193
-
-
Al-Ali, J.1
Siddique, I.2
Varghese, R.3
-
42
-
-
34250625319
-
Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection
-
Roulot D, Bourcier V, Grando V, et al. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. Journal of Viral Hepatitis. 2007;14:460-7.
-
(2007)
Journal of Viral Hepatitis
, vol.14
, pp. 460-467
-
-
Roulot, D.1
Bourcier, V.2
Grando, V.3
-
43
-
-
68949098506
-
Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4
-
El Makhzangy H, Esmat G, Said M, et al. Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. J Med Virol. 2009;81(9):1576-83.
-
(2009)
J Med Virol
, vol.81
, Issue.9
, pp. 1576-1583
-
-
El Makhzangy, H.1
Esmat, G.2
Said, M.3
-
44
-
-
79959618797
-
Hepatitis C virus genotype 4 with normal transaminases: Histological changes, schistosomiasis and response to treatment
-
Derbala MF, Amer AM, Almohanadi M, et al. Hepatitis C virus genotype 4 with normal transaminases: histological changes, schistosomiasis and response to treatment. J Viral Hepat. 2011;18 (7):e258-62.
-
(2011)
J Viral Hepat
, vol.18
, Issue.7
-
-
Derbala, M.F.1
Amer, A.M.2
Almohanadi, M.3
-
45
-
-
64949119373
-
Treatment of chronic hepatitis C genotype 4 with peginterferon alpha-2a plus ribavirin
-
Varghese R, Al-Khaldi J, Asker H, et al. Treatment of chronic hepatitis C genotype 4 with peginterferon alpha-2a plus ribavirin. Hepatogastroenterology. 2009;56(89):218-22.
-
(2009)
Hepatogastroenterology
, vol.56
, Issue.89
, pp. 218-222
-
-
Varghese, R.1
Al-Khaldi, J.2
Asker, H.3
-
46
-
-
37749046123
-
Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response
-
Kamal SM, Elkamary SS, Shardell MD, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response. Hepatology. 2007;46:1732-40.
-
(2007)
Hepatology
, vol.46
, pp. 1732-1740
-
-
Kamal, S.M.1
Elkamary, S.S.2
Shardell, M.D.3
|